Keywords: Biosimilars uptake, Prospects, Difficulties, Approval pathway

Likelihood of big uptake of biosimilars by 2020 questioned

Article | 15 March 2012

The engine of the biosimilar sector is the same as with small molecule drugs, patent expiry. On this basis, prospects ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in